Navigation Links
BSP Granted CE Mark for its HyperQ AD-100 Product Enabling Improved Diagnostic Performance of Stress ECG
Date:6/29/2010

TEL AVIV, Israel, June 29, 2010 /PRNewswire-FirstCall/ -- BSP, which develops and commercializes advanced products for the non invasive, accurate diagnosis of heart diseases, announced today that its Add-On product, the HyperQ AD-100 (http://www.bsp.co.il/pdf/HyperQ AD-100 Pic.pdf), intended for improved diagnostic performance of Stress ECG, has been granted the European CE conformance mark. The HyperQ AD-100 product is an add-on system with the HyperQ technology which is incorporated in parallel to existing standard stress ECG systems. The integration of the HyperQ AD-100 into Stress ECG systems enables accurate and sensitive diagnosis of Ischemic Heart Disease, a leading cause of death in the world.

The unique technology developed by BSP is implemented in a non invasive manner and does not involve exposure to radiation or other hazards to patients. It is highly effective in diagnosing sick people and in ruling out disease in healthy individuals. The HyperQ AD-100 enables physicians to benefit from the clinical advantages of the technology without the need to replace their existing installed Stress ECG system.

BSP CEO, Nissim Greisas: "The integration of the HyperQ Add-On systems into the vast installed base of standard Stress ECG systems significantly expands our potential global market. The worldwide annual stress ECG system market is estimated at $200M, and the total standard ECG installed base represents an estimated $800M market for the new product."

CE mark was also granted to BSP's software product - the HyperQ-AN. This product enables analysis with the unique HyperQ technology and can be employed in OEM and licensing business models in existing commercial stress ECG systems, such as the company's collaboration with Schiller AG.

About BSP

Founded in 2000, BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of cardiovascular disease. BSP's proprietary HyperQ(TM) technology is implemented in cardiac systems that offer accurate, low-cost and risk free cardiac monitoring and allows, for the first time, an effective diagnosis of ischemic heart disease in broad populations. BSP is a traded company on the Tel Aviv Stock Exchange since 2006 (TASE:BSP). The company's international offices are located in Tel Aviv, Israel and Rockville, Maryland, USA.

    For more information please contact:

    Nissim Greisas, CEO, Biological Signal Processing Ltd.
    nissim@bspmedical.com
    Tel. +972-3-6474840



'/>"/>
SOURCE BSP - Biological Signal Processing Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
2. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
3. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
4. Acuo Technologies Announces Patent Granted for Asset Communication Format Within a Computer Network
5. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
6. SPO Medical Granted Innovative Baby Monitoring Patent
7. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
8. FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity
9. Emergency Use Authorization Granted For BioCrysts Peramivir
10. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
11. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016   Click here for ... Inc. (NYSE: DPLO), the nation,s largest independent specialty ... definitive agreement to acquire Valley Campus Pharmacy, Inc., ... a leading specialty pharmacy that provides individualized patient ... . In 2015, TNH generated approximately $400 ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Metabolic Nutrition ... at this week’s 2016 Europa Games Get Fit and Sports Expo in ... the Europa Orlando Expo coming up April 29-30, was selected as the perfect event ...
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... an invitation to those affected by a health insurance co-operative bankruptcy to ... proprietary process, individuals can receive over 1,500 FDA-approved prescription medications from over ...
(Date:4/28/2016)... ... April 28, 2016 , ... Today ... the Protocol Calendar Exchange , is officially open to all sponsors in ... available for sites to download into their clinical trial management system (CTMS), which ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... Chief Medical Officer at the Steadman Philippon Research Institute in Vail, Colorado, ... to raise awareness about the debilitating and costly musculoskeletal disorders that are ...
Breaking Medicine News(10 mins):